Showing 2711-2720 of 6036 results for "".
- High-Tech Imaging Offers New Way to Detect Signs of Early Glaucomahttps://modernod.com/news/high-tech-imaging-offers-new-way-to-detect-signs-of-early-glaucoma/2481008/A new, noninvasive ocular imaging method may be able to detect an early indicator of glaucoma in time to prevent disease progression and vision loss, according to a new study from New York Eye and Ear Infirmary of Mount Sinai (NYEE). The study was published in the July/August issue of Op
- New App Designed to Use Artificial Intelligence to Reduce Digital Eye Strainhttps://modernod.com/news/new-app-designed-to-use-artificial-intelligence-to-reduce-digital-eye-strain/2481004/Robin Kuriakose, MD, a fellow physician in cornea and refractive surgery at the Northwestern Memorial Hospital, has launched SightKick, a new MacOS application designed to reduce digital eye strain: SightKick. Digital eye strain is a gr
- AcuFocus Receives FDA Approval for the IC-8 Apthera IOL, the First and Only Small Aperture Lenshttps://modernod.com/news/acufocus-announces-fda-approval-for-the-ic-8-apthera-iol-the-first-and-only-small-aperture-lens-for-cataract-surgery/2480986/AcuFocus has received FDA approval for its IC-8 Apthera IOL, the first and only non-toric extended depth-of-focus IOL approved for the 82% of cataract patients who have as much as 1.5 diopters (D) of corneal astigmatism.2 “We are delighted to receive
- Carl Zeiss Meditec and Precise Bio Announce Partnership in the Development and Commercialization of Tissue-Based Implants for Ophthalmologyhttps://modernod.com/news/carl-zeiss-meditec-and-precise-bio-announce-partnership-in-the-development-and-commercialization-of-tissue-based-implants-for-ophthalmology/2480984/Carl Zeiss Meditec and Precise Bio, a regenerative medicine company advancing the use of bio-printed tissues and organs, announced that the companies have entered into a partnership to develop and commercialize fabricated corneal tissue for transplants in patients that require endothelial ke
- Opus Genetics Expands its Leadership Teamhttps://modernod.com/news/opus-genetics-expands-its-leadership-team/2480981/Opus Genetics, a gene therapy company developing treatments for inherited retinal diseases, announced the appointments of Vikram Arora, PhD, DABT, as Vice President of Non-Clinical Development; Erin O’Neil, MD, as Vice President of Clinical Development; and Sarah Tuller, JD, RAC, as Vice Pr
- Avista Therapeutics Partners with Roche to Develop Next-Generation AAV Gene Therapy Vectors for Ocular Diseaseshttps://modernod.com/news/avista-therapeutics-partners-with-roche-to-develop-next-generation-aav-gene-therapy-vectors-for-ocular-diseases/2480977/Avista Therapeutics, which recently launched as a spinout of the University of Pittsburgh Medical Center (UPMC), announced a partnership with Roche to develop novel AAV gene therapy vectors for the eyes. The partnership aims to apply Avista’s single-cell adeno-associated
- Apellis Presents New Phase 3 DERBY and OAKS Data of Intravitreal Pegcetacoplan for GAhttps://modernod.com/news/apellis-presents-new-phase-3-derby-and-oaks-data-of-intravitreal-pegcetacoplan-for-ga/2480970/Apellis Pharmaceuticals announced that five oral presentations and two on-demand papers are being highlighted at the American Society of Retina Specialists Annual Scientific Meeting taking place July 13 -16, 2022 in New York City. New data include
- Waldo Launches Hydra Boost Plus Lenses in the United Stateshttps://modernod.com/news/waldo-launches-hydra-boost-plus-lenses-in-the-united-states/2480962/Waldo announced the launch of Hydra Boost Plus contact lenses, now available at
- Global Data: Increasing Cataract Surgical Rates Will Drive Artificial Lenses Market to Reach $4.7 Billion by 2030https://modernod.com/news/global-data-increasing-cataract-surgical-rates-will-drive-artificial-lenses-market-to-reach-47-billion-by-2030/2480953/The global market for IOLs is forecast by GlobalData to steadily grow from $4.3 billion in 2021 to $4.7 billion by the end of the decade. The data and analytics company notes that this growth is primarily driven by the growing capacity of many hospitals and clinics across all regions to perform m
- Novartis Acquires Kedalion Therapeutics and its Ocular Delivery Platformhttps://modernod.com/news/novartis-acquires-kedalion-therapeutics-and-its-ocular-delivery-platform/2480952/Novartis announced that it has acquired Kedalion Therapeutics and its AcuStream technology, a device that may have the potential to facilitate precise dosing and accurate delivery of certain topical ophthalmic medications to the eye.1,2 Terms of the deal were